{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:11:56Z","timestamp":1789708316831,"version":"4.0.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2008,4,23]],"date-time":"2008-04-23T00:00:00Z","timestamp":1208908800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1007\/s00280-008-0755-1","type":"journal-article","created":{"date-parts":[[2008,4,22]],"date-time":"2008-04-22T19:47:14Z","timestamp":1208893634000},"page":"707-716","source":"Crossref","is-referenced-by-count":33,"title":["Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4"],"prefix":"10.1007","volume":"62","author":[{"given":"Z.-Y.","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. M.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. D.","family":"Pelletier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. N.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,4,23]]},"reference":[{"key":"755_CR1","doi-asserted-by":"crossref","first-page":"5547","DOI":"10.1016\/j.bmcl.2004.08.068","volume":"14","author":"BM Seletsky","year":"2004","unstructured":"Seletsky BM, Wang Y, Hawkins LD et al (2004) Structurally simplified macrolactone analogues of halichondrin B. Bioorg Med Chem Lett 14:5547\u20135550","journal-title":"Bioorg Med Chem Lett"},{"key":"755_CR2","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1124\/mol.106.026641","volume":"70","author":"DA Dabydeen","year":"2006","unstructured":"Dabydeen DA, Burnett JC, Bai R et al (2006) Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. Mol Pharmacol 70:1866\u20131875","journal-title":"Mol Pharmacol"},{"key":"755_CR3","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1158\/1535-7163.MCT-04-0345","volume":"4","author":"MA Jordan","year":"2005","unstructured":"Jordan MA, Kamath K, Manna T et al (2005) The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 4:1086\u20131095","journal-title":"Mol Cancer Ther"},{"key":"755_CR4","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1158\/0008-5472.CAN-04-1169","volume":"64","author":"G Kuznetsov","year":"2004","unstructured":"Kuznetsov G, Towle MJ, Cheng H et al (2004) Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res 64:5760\u20135766","journal-title":"Cancer Res"},{"key":"755_CR5","first-page":"1013","volume":"61","author":"MJ Towle","year":"2001","unstructured":"Towle MJ, Salvato KA, Budrow J et al (2001) In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 61:1013\u20131021","journal-title":"Cancer Res"},{"key":"755_CR6","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1200\/jco.2007.25.18_suppl.1034","volume":"25","author":"J Blum","year":"2007","unstructured":"Blum J, Pruitt B, Fabian C et al (2007) Phase II study of eribulin mesylate (E7389) halichondrin B analog in patients with refractory breast cancer. J Clin Oncol 25:1034","journal-title":"J Clin Oncol"},{"key":"755_CR7","unstructured":"Desai KK, Goel S, Mita A et al (2005) Dose escalation and pharmacokinetic (pk) study of E7389, a microtubule-binding drug in patients (pts) with advanced solid tumors. J Clin Oncol 23:16s 3090"},{"key":"755_CR8","doi-asserted-by":"crossref","unstructured":"Rubin EH, Rosen L, Rajeev V et al (2005) Phase I study of E7389 administered by 1 hour infusion every 21\u00a0days. J Clin Oncol 23:148s 2054","DOI":"10.1200\/jco.2005.23.16_suppl.2054"},{"key":"755_CR9","doi-asserted-by":"crossref","unstructured":"Spira AI, Iannotti NO, Savin MA et al (2007) Phase II study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 25:18s 7546","DOI":"10.1200\/jco.2007.25.18_suppl.7546"},{"key":"755_CR10","doi-asserted-by":"crossref","unstructured":"Synold TW, Morgan RJ, Newman EM et al (2005) A phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: a California Cancer consortium trial. J Clin Oncol 23:200s 3036","DOI":"10.1200\/jco.2005.23.16_suppl.3036"},{"key":"755_CR11","doi-asserted-by":"crossref","unstructured":"Kostrubsky VE, Lewis LD, Strom SC et al (1998) Induction of cytochrome P4503A by taxol in primary cultures of human hepatocytes. Arch Biochem Biophys 355: 131\u2013136","DOI":"10.1006\/abbi.1998.0730"},{"key":"755_CR12","first-page":"414","volume":"270","author":"T Shimada","year":"1994","unstructured":"Shimada T, Yamazaki H, Mimura M et al (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414\u2013423","journal-title":"J Pharmacol Exp Ther"},{"key":"755_CR13","first-page":"1160","volume":"268","author":"GN Kumar","year":"1994","unstructured":"Kumar GN, Walle UK, Walle T (1994) Cytochrome P450 3A-mediated human liver microsomal taxol 6 alpha-hydroxylation. J Pharmacol Exp Ther 268:1160\u20131165","journal-title":"J Pharmacol Exp Ther"},{"key":"755_CR14","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2174\/1389200043335450","volume":"5","author":"S Zhou","year":"2004","unstructured":"Zhou S, Chan E, Lim LY et al (2004) Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr Drug Metab 5:415\u2013442","journal-title":"Curr Drug Metab"},{"key":"755_CR15","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/nrc1887","volume":"6","author":"CD Scripture","year":"2006","unstructured":"Scripture CD, Figg WD (2006) Drug interactions in cancer therapy. Nat Rev Cancer 6:546\u2013558","journal-title":"Nat Rev Cancer"},{"key":"755_CR16","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/ptr.1841","volume":"20","author":"S HemaIswarya","year":"2006","unstructured":"HemaIswarya S, Doble M (2006) Potential synergism of natural products in the treatment of cancer. Phytother Res 20:239\u2013249","journal-title":"Phytother Res"},{"key":"755_CR17","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1021\/ja01473a020","volume":"83","author":"BD West","year":"1961","unstructured":"West BD, Preis S, Schroeder CH et al (1961) Studies on the 4-hydroxycoumarins. XVII. The resolution and absolute configuration of warfarin. Am Chem Soc 83:2676\u20132679","journal-title":"Am Chem Soc"},{"key":"755_CR18","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1124\/dmd.104.000547","volume":"32","author":"MF Paine","year":"2004","unstructured":"Paine MF, Criss AB, Watkins PB (2004) Two major grapefruit juice components differ in intestinal CYP3A4 inhibition kinetic and binding properties. Drug Metab Dispos 32:1146\u20131153","journal-title":"Drug Metab Dispos"},{"key":"755_CR19","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1124\/dmd.31.4.432","volume":"31","author":"H Nakamura","year":"2003","unstructured":"Nakamura H, Torimoto N, Ishii I et al (2003) CYP3A4 and CYP3A7-mediated carbamazepine 10, 11-epoxidation are activated by differential endogenous steroids. Drug Metab Dispos 31:432\u2013438","journal-title":"Drug Metab Dispos"},{"key":"755_CR20","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1365-2125.1994.tb04336.x","volume":"38","author":"T Andersson","year":"1994","unstructured":"Andersson T, Miners JO, Veronese ME et al (1994) Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. Br J Clin Pharmacol 38:131\u2013137","journal-title":"Br J Clin Pharmacol"},{"key":"755_CR21","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1124\/dmd.30.8.869","volume":"30","author":"HK Crewe","year":"2002","unstructured":"Crewe HK, Notley LM, Wunsch RM et al (2002) Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4\u2019-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos 30:869\u2013874","journal-title":"Drug Metab Dispos"},{"key":"755_CR22","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0090-9556(24)15374-3","volume":"28","author":"RW Wang","year":"2000","unstructured":"Wang RW, Newton DJ, Liu N et al (2000) Human cytochrome P-450 3A4: in vitro drug\u2013drug interaction patterns are substrate-dependent. Drug Metab Dispos 28:360\u2013366","journal-title":"Drug Metab Dispos"},{"key":"755_CR23","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1124\/dmd.30.7.795","volume":"30","author":"G Luo","year":"2002","unstructured":"Luo G, Cunningham M, Kim S et al (2002) CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 30:795\u2013804","journal-title":"Drug Metab Dispos"},{"key":"755_CR24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1006\/abio.2001.5383","volume":"298","author":"ZY Zhang","year":"2001","unstructured":"Zhang ZY, King BM, Wong YN (2001) Quantitative liquid chromatography\/mass spectrometry\/mass spectrometry warfarin assay for in vitro cytochrome P450 studies. Anal Biochem 298:40\u201349","journal-title":"Anal Biochem"},{"key":"755_CR25","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1124\/dmd.30.7.805","volume":"30","author":"ZY Zhang","year":"2002","unstructured":"Zhang ZY, King BM, Mollova NN et al (2002) In vitro interactions between a potential muscle relaxant E2101 and human cytochromes P450. Drug Metab Dispos 30:805\u2013813","journal-title":"Drug Metab Dispos"},{"key":"755_CR26","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/(SICI)1099-081X(199704)18:3<213::AID-BDD15>3.0.CO;2-0","volume":"18","author":"MH Court","year":"1997","unstructured":"Court MH, Von Moltke LL, Shader RI et al (1997) Biotransformation of chlorzoxazone by hepatic microsomes from humans and ten other mammalian species. Biopharm Drug Dispos 18:213\u2013226","journal-title":"Biopharm Drug Dispos"},{"key":"755_CR27","unstructured":"Engel PC (1996) (eds) Enzymology Labfax. BIOS Scientific Publishers Limited, Oxford"},{"key":"755_CR28","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/S0090-9556(24)15316-0","volume":"27","author":"T Kakkar","year":"1999","unstructured":"Kakkar T, Boxenbaum H, Mayersohn M (1999) Estimation of Ki in a competitive enzyme-inhibition model: comparisons among three methods of data analysis. Drug Metab Dispos 27:756\u2013762","journal-title":"Drug Metab Dispos"},{"key":"755_CR29","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1001\/jama.1993.03500120051025","volume":"269","author":"PK Honig","year":"1993","unstructured":"Honig PK, Wortham DC, Zamani K et al (1993) Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 269:1513\u20131518","journal-title":"JAMA"},{"key":"755_CR30","first-page":"138s","volume":"23","author":"N Wong","year":"2005","unstructured":"Wong N, Desjardins C, Silberman S et al (2005) Pharmacokinetics (PK) of E7389, a Halichodrin B analog with novel anti-tubulin activity: results of two phase I studies with different schedules of administration. J Clin Oncol 23:138s","journal-title":"J Clin Oncol"},{"key":"755_CR31","first-page":"E25","volume":"4","author":"K Ito","year":"2002","unstructured":"Ito K, Chiba K, Horikawa M et al (2002) Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data? AAPS PharmSci 4:E25","journal-title":"AAPS PharmSci"},{"key":"755_CR32","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.bbrc.2005.12.203","volume":"341","author":"ZY Zhang","year":"2006","unstructured":"Zhang ZY, Pelletier RD, Wong YN et al (2006) Preferential inducibility of CYP1A1 and CYP1A2 by TCDD: differential regulation in primary human hepatocytes versus transformed human cells. Biochem Biophys Res Commun 341:399\u2013407","journal-title":"Biochem Biophys Res Commun"},{"key":"755_CR33","doi-asserted-by":"crossref","first-page":"13634","DOI":"10.1021\/ja053809q","volume":"127","author":"H Park","year":"2005","unstructured":"Park H, Lee S, Suh J (2005) Structural and dynamical basis of broad substrate specificity, catalytic mechanism, and inhibition of cytochrome P450 3A4. J Am Chem Soc 127:13634\u201313642","journal-title":"J Am Chem Soc"},{"key":"755_CR34","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0165-6147(03)00049-X","volume":"24","author":"S Ekins","year":"2003","unstructured":"Ekins S, Stresser DM, Williams JA (2003) In vitro and pharmacophore insights into CYP3A enzymes. Trends Pharmacol Sci 24:161\u2013166","journal-title":"Trends Pharmacol Sci"},{"key":"755_CR35","doi-asserted-by":"crossref","first-page":"13682","DOI":"10.1073\/pnas.0603236103","volume":"103","author":"M Ekroos","year":"2006","unstructured":"Ekroos M, Sjogren T (2006) Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc Natl Acad Sci USA 103:13682\u201313687","journal-title":"Proc Natl Acad Sci USA"},{"key":"755_CR36","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2174\/1389200054021834","volume":"6","author":"ZY Zhang","year":"2005","unstructured":"Zhang ZY, Wong YN (2005) Enzyme kinetics for clinically relevant CYP inhibition. Curr Drug Metab 6:241\u2013257","journal-title":"Curr Drug Metab"},{"key":"755_CR37","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0022-3565(24)29553-7","volume":"297","author":"Y Oda","year":"2001","unstructured":"Oda Y, Kharasch ED (2001) Metabolism of levo-alpha-Acetylmethadol (LAAM) by human liver cytochrome P450: involvement of CYP3A4 characterized by atypical kinetics with two binding sites. J Pharmacol Exp Ther 297:410\u2013422","journal-title":"J Pharmacol Exp Ther"},{"key":"755_CR38","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1126\/science.1099736","volume":"305","author":"PA Williams","year":"2004","unstructured":"Williams PA, Cosme J, Vinkovic DM et al (2004) Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science 305:683\u2013686","journal-title":"Science"},{"key":"755_CR39","doi-asserted-by":"crossref","first-page":"11866","DOI":"10.1021\/ja027552x","volume":"124","author":"MJ Dabrowski","year":"2002","unstructured":"Dabrowski MJ, Schrag ML, Wienkers LC et al (2002) Pyrene.pyrene complexes at the active site of cytochrome P450 3A4: evidence for a multiple substrate binding site. J Am Chem Soc 124:11866\u201311867","journal-title":"J Am Chem Soc"},{"key":"755_CR40","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1124\/dmd.31.9.1108","volume":"31","author":"A Galetin","year":"2003","unstructured":"Galetin A, Clarke SE, Houston JB (2003) Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine. Drug Metab Dispos 31:1108\u20131116","journal-title":"Drug Metab Dispos"},{"key":"755_CR41","doi-asserted-by":"crossref","first-page":"9127","DOI":"10.1074\/jbc.M511375200","volume":"281","author":"EM Isin","year":"2006","unstructured":"Isin EM, Guengerich FP (2006) Kinetics and thermodynamics of ligand binding by cytochrome P450 3A4. J Biol Chem 281:9127\u20139136","journal-title":"J Biol Chem"},{"key":"755_CR42","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0163-7258(96)00140-4","volume":"73","author":"LS Kaminsky","year":"1997","unstructured":"Kaminsky LS, Zhang ZY (1997) Human P450 metabolism of warfarin. Pharmacol Ther 73:67\u201374","journal-title":"Pharmacol Ther"},{"key":"755_CR43","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00280-004-0799-9","volume":"54","author":"SC Nallani","year":"2004","unstructured":"Nallani SC, Goodwin B, Buckley AR et al (2004) Differences in the induction of cytochrome P450 3A4 by taxane anticancer drugs, docetaxel and paclitaxel, assessed employing primary human hepatocytes. Cancer Chemother Pharmacol 54:219\u2013229","journal-title":"Cancer Chemother Pharmacol"},{"key":"755_CR44","unstructured":"Zheng W, Seletsky BM, Palme MH, Habgood GJ, Singer LA, DiPietro LV, Chen JJ, Lydon PJ, Quincy DA, Towle MJ, Salvato KA, Wels BF, Kuznetsov G, Aalfs KK, Kishi Y, Lewis MD, Littlefield BA, Yu MJ (2003) Structure-activity relationships of synthetic halichondrin B analog E7389: in vitro susceptibility to PgP-mediated drug efflux (abstract 2751). In: Annual meeting of the American Association for Cancer Research, Washington DC, 11\u201314 July 2003"},{"key":"755_CR45","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00232-005-0792-1","volume":"206","author":"TW Loo","year":"2005","unstructured":"Loo TW, Clarke DM (2005) Recent progress in understanding the mechanism of P-glycoprotein-mediated drug efflux. J Membr Biol 206:173\u2013185","journal-title":"J Membr Biol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-008-0755-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-008-0755-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-008-0755-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T21:22:31Z","timestamp":1738185751000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-008-0755-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,23]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["755"],"URL":"https:\/\/doi.org\/10.1007\/s00280-008-0755-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,23]]}}}